Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cambrex to Acquire ProSyntest | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cambrex to Acquire ProSyntest

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cambrex Karlskoga AB, a subsidiary of Cambrex Corp., has entered into an agreement to acquire ProSyntest AS, a privately held API R&D company. ProSyntest employs 25 chemists at its Tallinn Technology Park location in Tallinn, Estonia. ProSyntest has expertise in chemical route selection and sample generation, rapid scaleup of products at kilo lab scale, as well as chiral and organometallic chemistries.

The business will be renamed Cambrex Tallinn and Cambrex plans to add more process and analytical chemists at the site and continue early API development work in Tallinn for scale up at Karlskoga and the other Cambrex manufacturing facilities.

“Cambrex Karlskoga has successfully worked with the ProSyntest chemists for the past 15 years, and the acquisition of the business is a natural extension of our long-standing relationship. ProSyntest, located in Eastern Europe, will enable Cambrex to more effectively compete in the high growth early clinical stage pharmaceutical custom development market and provide us with a strong pool of talented chemists to advance numerous proprietary strategic initiatives,” commented Steven Klosk, executive vice president and chief operating officer of Cambrex Corp.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters